Time-series expression patterns of Edar and Xedar as predictive markers in breast cancer: A New Paradigm for Personalized Treatment

Author: Slawomir A. Wisniewski, SCI4BIZ Research & Development Dept.
e-mail: sa.wisniewski@sci4biz.edu.pl

ABSTRACT:
Time-series analysis of gene expression patterns has become a powerful tool in cancer monitoring. A novel predictive model based on the temporal expression patterns of the Edar and Xedar genes in breast cancer is proposed here. This approach is based on recent discoveries that show distinct temporal regulation of these genes during normal development and their critical role in mammary gland morphogenesis. By tracking dynamic changes in EDAR and XEDAR expression, this model aims to detect resistance to treatment and disease progression earlier than conventional monitoring methods. Implementing this system could potentially reduce mortality in the overall population of breast cancer, up to 46,000-69,000 lives per year worldwide. This conceptual framework offers a new paradigm for personalized cancer monitoring, integrating developmental biology principles with clinical oncology.

KEYWORDS: predictive modeling, gene expression monitoring, breast cancer, EDAR, XEDAR, personalized medicine, temporal analysis, response to treatment, biomarkers, disease progression

INTRODUCTION

Breast cancer remains one of the most challenging malignancies worldwide, with approximately 2.3 million new cases diagnosed annually (Bray et al., 2021; Sung et al., 2021). Despite advances in treatment options, the ability to monitor disease progression and response to treatment in real time remains limited. Based primarily on imaging and traditional biomarkers, current monitoring methods often detect changes only after significant disease progression.

The Ectodysplasin (Eda) signaling pathway, traditionally associated with ectodermal development, has become crucial in the development and function of the mammary gland. Recent studies have demonstrated that Eda signaling, mainly through its receptors Edar and Xedar, plays an essential role in mammary epithelial growth and branching morphogenesis (Wark et al., 2023). Furthermore, these receptors exhibit distinct temporal expression patterns during normal development, suggesting their potential role as indicators of tissue differentiation states.

Recent developmental studies have revealed precise temporal regulation of Edar and Xedar expression during tissue specification and differentiation (Wisniewski, 2024). These findings demonstrated that the expression patterns of these genes correlate strongly with specific developmental stages and tissue fate decisions. The observation that changes in expression levels often precede morphological changes is particularly noteworthy, suggesting their potential as early indicators of tissue state transitions.

Current approaches to monitoring breast cancer progression and response to treatment rely heavily on periodic imaging studies and the measurement of established biomarkers such as CA 15-3 and CEA (Chen et al., 2023; Dawson et al., 2013). However, these methods often lack the sensitivity to detect early changes in disease trajectory or treatment response. This limitation often results in delayed recognition of treatment failure and missed opportunities for early intervention.

Here, a novel paradigm for monitoring breast cancer progression and response to treatment is proposed based on a time-series analysis of Edar and Xedar expression patterns. This approach

parallels developmental regulation and cancer progression, potentially offering earlier and more precise indicators of changes in disease trajectory.

CONCEPTUAL FRAMEWORK

The foundation of this proposed monitoring approach lies in understanding the parallels between developmental processes and cancer progression (Fan et al., 2023). This framework builds upon two key observations: the highly regulated temporal expression patterns of developmental genes and the reactivation of developmental pathways in cancer (Fig. 1).

1. Developmental Expression Patterns as a Model

Recent developmental studies have revealed precise temporal regulation of Edar and Xedar during tissue specification (Wisniewski, 2024; Wark et al., 2023)). Key features of these patterns include the following:

- Species-specific temporal regulation correlating with different morphological outcomes
- Different expression peaks corresponding to critical developmental transitions
- Predictable ratios between the expression of Edar and Xedar in specific developmental stages

These patterns serve as "molecular timestamps" of tissue state, with specific expression profiles characterizing distinct developmental stages. These molecular signatures of development may provide crucial information about cancer progression (Linnarsson and Teichmann, 2023). In normal mammary gland development, Xedar expression is significant during epithelial growth and branching phases (Wark et al., 2023), suggesting its potential relevance in monitoring aberrant growth in cancer.

2. Translation to Cancer Progression

The application of developmental expression patterns to cancer monitoring is based on several fundamental principles.

Molecular Parallels:

- Cancer cells often reactivate developmental pathways (Wisniewski, 2024a).
- Expression patterns may reflect the "developmental state" of tumor cells.
- Changes in expression ratios could indicate transitions in tumor behavior.

Temporal Dynamics:

- Regular monitoring could reveal progression patterns.
- Expression changes may precede morphological changes
- Treatment responses might be reflected in expression pattern alterations.

Critical Points:

- Specific expression profiles might indicate tumor state transitions
- Changes in EDAR/XEDAR ratios could signal resistance to treatment.
- Pattern disruptions might predict metastatic potential.

This framework suggests that by monitoring the expression of EDAR and XEDAR over time, it is potentially possible:

1. Identify early indicators of disease progression
2. Predict treatment response before conventional markers
3. Recognize critical transition points that require intervention

PROPOSED PREDICTIVE MODEL

The successful implementation of expression pattern monitoring requires careful consideration of sampling frequency and timing (Fig. 2). The potential for using liquid biopsies for frequent monitoring has been demonstrated in various contexts (Chen et al., 2023; Dawson et al., 2013). A systematic monitoring schedule is proposed to align with the critical phases of treatment and

disease progression to establish reliable baseline data and track meaningful changes. Initial measurements at diagnosis provide essential baseline data, while pretreatment sampling captures any changes that could occur during the diagnostic period. The early response phase, particularly critical to understanding the effectiveness of treatment, requires more frequent monitoring during the first two weeks of therapy. This intensive early monitoring period can capture rapid changes in expression patterns that might predict response to treatment.

Interpreting expression changes must be grounded in robust statistical thresholds derived from developmental studies and clinical observations. Previous developmental research (Wisniewski, 2024) provides crucial insights into the natural variation in Edar and Xedar expression. Significant changes are considered those that exceed normal biological variation while indicating potentially meaningful biological transitions. Changes in individual gene expression must be evaluated in the context of the overall expression pattern and the Edar/Xedar ratio, which has proven particularly informative in developmental contexts.

The mathematical modeling of expression patterns employs time series analysis techniques (Fan et al., 2023), specifically tailored to capture both short-term fluctuations and longer-term trends. The auto-regressive integrated moving average (ARIMA) approach incorporates recent expression history and overall trends while accounting for the natural variability in biological systems. This modeling framework can identify subtle pattern changes that might indicate disease progression or response to treatment before conventional clinical markers show significant changes.

Validation of predicted changes requires careful statistical consideration. The model's performance is assessed through multiple metrics, ensuring accuracy and clinical relevance. Notably, detecting critical transition points - moments when expression patterns indicate significant biological changes - requires robust statistical methods that can distinguish genuine shifts from normal variation. These transition points often precede clinical changes, potentially providing an early warning system for failure of treatment or progression of the disease.

This comprehensive monitoring approach integrates seamlessly with existing clinical workflows while providing additional layers of information for treatment decision-making. The ability of the system to detect subtle changes in expression patterns, validated through rigorous statistical analysis, offers clinicians new tools to optimize treatment timing and selection.

EXPECTED IMPACT

Implementing this predictive model offers potentially transformative benefits for breast cancer treatment and monitoring. Current global statistics indicate approximately 2.3 million new breast cancer diagnoses annually (Bray et al., 2021; Sung et al., 2021), with varying survival rates depending on the stage of diagnosis and treatment effectiveness. Analysis of current treatment patterns suggests that molecular monitoring systems could significantly improve patient outcomes (Chen et al., 2023). Analysis of current treatment patterns and possible improvements through early detection suggests that implementing this monitoring system could positively impact patient outcomes in several key areas.

Survival Benefits and Treatment Optimization

The impact on patient survival could be substantial, particularly among high-risk groups and those with advanced disease. Analysis of current treatment failure patterns suggests that earlier detection of resistance or progression could provide a crucial window for therapeutic intervention. In cases where conventional monitoring methods typically detect treatment failure after significant disease progression, molecular monitoring could enable intervention weeks or months earlier. Conservative estimates based on current survival data and the potential for earlier intervention suggest that improved monitoring could reduce mortality in the overall population of breast cancer, up to 46,000-69,000 lives annually around the world (Fig. 3).

Efficacy and utilization of treatment resources

Beyond survival metrics, this approach offers significant advantages for treatment optimization. Real-time molecular monitoring enables a more precise evaluation of treatment effectiveness, allowing for rapid adjustment of therapeutic strategies when needed. This capability is particularly valuable in cases where conventional imaging and biomarker assessments could delay recognition of resistance to treatment. Early identification of ineffective treatments can prevent patients from suffering unnecessary side effects while enabling a faster transition to alternative therapies. This improved treatment selection and timing efficiency could significantly reduce patients' physical and emotional burdens while optimizing healthcare resources.

Economic Considerations

The economic impact of implementing this monitoring system requires a careful analysis of both costs and benefits. Current analyses of healthcare care costs in breast cancer treatment (Bray et al., 2021) suggest that early intervention through improved monitoring could significantly reduce overall treatment costs. While initial implementation requires investment in infrastructure, training, and routine molecular testing, these costs must be weighed against potential savings. Reduced spending on ineffective treatments, fewer hospitalizations for advanced disease complications, and a more efficient use of expensive targeted therapies could offset implementation costs. Furthermore, improved treatment outcomes could reduce disability and earlier return to work, providing broader societal economic benefits.

Quality of Life Impact

The ability to more precisely monitor the effectiveness of treatment and predict disease progression earlier could significantly improve patient quality of life. Studies have shown that early detection and intervention can significantly improve patient outcomes and quality of life (Sung et al., 2021). Reducing the uncertainty associated with treatment response and providing earlier warning of potential progression could help patients and healthcare providers make more informed decisions about the continuation or modification of treatment. In addition, avoiding prolonged ineffective treatments could reduce cumulative toxicity and improve overall patient well-being.

Integration of the healthcare system

The successful implementation of this monitoring system could catalyze broader changes in the delivery of cancer care. Integrating molecular monitoring systems into clinical practice has shown promise in various oncological settings (Chen et al., 2023; Dawson et al., 2013). The system could facilitate more personalized treatment approaches by providing more precise and timely information about the effectiveness of treatment. This improved monitoring precision could also contribute to more efficient clinical trial designs and faster evaluation of new therapeutic strategies.

FUTURE DIRECTIONS

The successful implementation of this predictive model requires a comprehensive validation program. Initial clinical trials should focus on establishing the correlation between expression patterns and clinical outcomes in different subtypes and treatment regimens of breast cancer. These studies must include diverse patient populations to ensure the broad applicability and reliability of the model.

Technical development presents both challenges and opportunities. Although current molecular analysis techniques are sufficient for proof of concept (Linnarsson and Teichmann, 2023), optimizing clinical use requires more streamlined and cost-effective methods. The potential for

using liquid biopsies, if validated, could significantly improve the feasibility of frequent monitoring (Chen et al., 2023; Dawson et al., 2013). Parallel development of data analysis infrastructure is crucial, as the model's success depends on the rapid and reliable processing of complex molecular data.

Integration into clinical practice requires careful consideration of practical challenges. Healthcare providers need comprehensive training programs to effectively understand and use the new monitoring system. Regulatory requirements must be addressed, ensuring compliance with healthcare standards while maintaining the system's utility. Additionally, cooperation with insurance providers is essential to establish coverage for this novel monitoring approach.

This framework builds on recent developments in predictive modeling in oncology (Fan et al., 2023) while incorporating developmental biology principles (Wisniewski, 2024; Wark et al., 2023) for other types of cancer. The principles of using developmental gene expression patterns as predictive markers might apply to various malignancies. Furthermore, this approach could contribute to our understanding of cancer progression mechanisms, potentially leading to new therapeutic strategies.

Author Contributions Statement

SAW conceived and designed the study, performed the experiments, analyzed the data, wrote the manuscript, and approved the final version.

Conflict of Interest Statement

The author declares that there is no conflict of interest. The research was carried out without commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Bray, F., Ferlay, J., Soerjomataram, I., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249.
2. Chen, Z., Huang, Y., Li, S., et al. (2023). Liquid biopsy for cancer biomarker discovery: Present and future. Nature Reviews Clinical Oncology, 20(1), 1-17.
3. Dawson, S.J., Tsui, D.W., Murtaza, M., et al. (2013). Analysis of circulating tumor DNA to monitor metastatic breast cancer. New England Journal of Medicine, 368(13), 1199-1209.
4. Fan, G., Wang, Z., Hao, M., Li, J. (2023). Artificial intelligence in cancer prediction models: Current status and future directions. Frontiers in Oncology, 13, 1-15.
5. Linnarsson, S., Teichmann, S.A. (2023). Single-cell genomics: Coming of age. Nature Reviews Genetics, 24(1), 1-17.
6. Sung, H., Ferlay, J., Siegel, R.L., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(2), 209-249.
7. Wark, A.R., Aldea, D., Tomizawa, R.R., et al. (2023). Ectodysplasin Signaling Through XEDAR Is Required for Mammary Gland Morphogenesis. Journal of Investigative Dermatology, 143, 1529-1537.
8. Wisniewski, S.A. (2024). Differential expression of Edar and Xedar during mouse and rat tail appendage development. bioRxiv, https://doi.org/10.1101/2024.12.01.626243
9. Wisniewski, S.A. (2024a). The Development of Differentiation-Based Therapy for Breast Cancer Using EDAR and XEDAR Signaling Pathways: A Conceptual Framework. Qeios. https://doi.org/10.32388/1CLGH0

Figure legend

Fig. 1 Conceptual framework of the predictive model
A conceptual representation of the proposed predictive model for breast cancer monitoring. The model integrates liquid biopsy for sample collection, time series analysis of EDAR and XEDAR gene expression, and predictive analytics to identify disease progression or resistance to treatment. Arrows indicate the flow of data through the process.

Fig. 2 Temporal expression profiles of the EDAR and XEDAR genes
Hypothetical temporal profiles of normalized gene expression levels for EDAR and XEDAR. Key transitions are highlighted: a critical transition to the biological state (red line) and a potential indicator of resistance to treatment (blue line). These patterns demonstrate the utility of temporal dynamics in detecting early changes in tumor behavior or response to treatment.

Fig.3 Impact of the early intervention
Comparison of 5-year expected survival rates between conventional monitoring and early molecular monitoring. Although the percentage increase may seem modest, the impact translates into up to 46.000-69,000 lives saved annually worldwide.